Patent number: 12344610
Abstract: Provided herein are compounds of formula (II): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein wherein m, n, p, R1, R2, R3, L1, L2, L3, R4, X1, X2, X3, and X4 are as defined herein. Also provided are methods of preparing compounds of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided are methods of inhibiting APOL1 and methods of treating an APOL1-mediated disease, disorder, or condition in an individual.
Type:
Grant
Filed:
March 26, 2024
Date of Patent:
July 1, 2025
Assignee:
Maze Therapeutics, Inc.
Inventors:
Patrick Sang Tae Lee, Todd Jonathan August Ewing, Adam Neil Reid, Christopher Joseph Sinz, Birong Zhang, Sarah M. Bronner, David John Morgans, Jr., Maarten Hoek, Victoria Anne Assimon, Chris Ziebenhaus, Alexander Wayne Schammel